Tenet Healthcare reported strong Q3 2024 results, with net sales of $5.1 billion and adjusted EBITDA of $978 million, reflecting a 15% year-on-year growth. The company raised its full-year adjusted EBITDA guidance to between $3.9 billion and $4 billion, despite lower revenue forecasts due to hospital divestments. Tenet's strategic focus on capital deployment and share buybacks, alongside a projected free cash flow of up to $1.225 billion, positions it for continued growth in the healthcare sector.
